UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model

OBJECTIVES: In 2002, the UK's National Institute for Health and Care Excellence concluded that the multiple sclerosis (MS) disease modifying therapies; interferon-β and glatiramer acetate, were not cost effective over the short term but recognised that reducing disability over the longer term m...

Descripción completa

Detalles Bibliográficos
Autores principales: Palace, Jacqueline, Bregenzer, Thomas, Tremlett, Helen, Oger, Joel, Zhu, Fheng, Boggild, Mike, Duddy, Martin, Dobson, Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2014
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902459/
https://www.ncbi.nlm.nih.gov/pubmed/24441054
http://dx.doi.org/10.1136/bmjopen-2013-004073

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902459/
https://www.ncbi.nlm.nih.gov/pubmed/24441054
http://dx.doi.org/10.1136/bmjopen-2013-004073

Ejemplares similares